Anorexia Clinical Trial
— ESATRALOfficial title:
Impact of a Supervised Physical Exercise Program (ESATRAL) in Patients With Anorexia Nervosa After Hospital Discharge
Verified date | May 2022 |
Source | Fundación Universidad Católica de Valencia San Vicente Mártir |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Excessive physical exercise is one of the main symptoms of anorexia and a common restrictive behavior used by patients, which is associated with less short- and long-term treatment success. Supervised exercise has shown these benefits in patients with anorexia: opportunity to learn and acquire knowledge and information on how to perform physical activity in a healthy, safe and moderate way, less feelings of incapacity; lower risk of relapse; prohibiting exercise during treatment can increase the likelihood that patients will revert to old patterns once therapy is completed. Exercise can be as effective as antidepressants and psychological therapies to treat some cases of depression present in anorexia. The objective of the ESATRAL program is to analyze the physiological, psychological, body composition, physical condition and functionality effects of a supervised strength-focused training program in patients with anorexia nervosa after hospital discharge. All participants are assessed at baseline, after 12 weeks, post-treatment (24 weeks), and at 9 months' post follow-up (36 weeks).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 30, 2023 |
Est. primary completion date | July 30, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 16 Years to 45 Years |
Eligibility | Inclusion Criteria: - Women with a BMI higher than 15 Kg / m2, - aged between 16 to 45 years old, - diagnosed with restrictive (DSM-V F50.01) or purgative (F50.02 (DSM-V) anorexia. - Patients from the 24 h or Day Hospital and ambulatory. - who has agreed to participate in the study and signed the informed consent or in case of being minors, their father / mother / legal guardian signs the participation consent. Exclusion Criteria: - Patients with contraindication in the performance of physical exercise (cardiovascular risk factors), - patients with severe mental disorder (major depressive episode, bipolar disorder, severe personality disorders, schizophrenia) - Patients who refuse to sign the informed consent. |
Country | Name | City | State |
---|---|---|---|
Spain | Ita Previ Valencia | Valencia |
Lead Sponsor | Collaborator |
---|---|
Fundación Universidad Católica de Valencia San Vicente Mártir | ITA PREVI Valencia, PERFORMA Salud S.L. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Risk of eating disorders | The Eating Disorder Inventory-3 will be used. It made up of 91 items organized into 12 subscales (3 specific to eating disorders and 9 general psychological scales). It uses a 0-4 point scoring system. Higher scores indicating greater risk of an eating disorder. | Base line, week 12, week 24, week 36 | |
Primary | Changes in Maximal strength horizontal pull based on the execution velocity. | Difference in muscle strength measured with horizontal pull strength tests in patients treated with standard treatment compared to patients treated with ESATRAL. To measure muscle strength we will use a linear encoder (T-FORCE dynamic measurement system) to achieve the movement speed. The exercise will be done in a Smith Machine. | Base line, week 12, week 24, week 36 | |
Primary | Changes in Maximal strength bench press based on the execution velocity. | Difference in muscle strength measured with horizontal bench press tests in patients treated with standard treatment compared to patients treated with ESATRAL. To measure muscle strength we will use a linear encoder (T-FORCE dynamic measurement system) to achieve the movement speed. The exercise will be done in a Smith Machine. | Base line, week 12, week 24, week 36 | |
Primary | Changes in Maximal strength squat based on the execution velocity. | Difference in muscle strength measured with squat tests in patients treated with standard treatment compared to patients treated with ESATRAL. To measure muscle strength we will use a linear encoder (T-FORCE dynamic measurement system) to achieve the movement speed. The exercise will be done in a Smith Machine. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in Blood pressure | Changes related to blood pressure (systolic and diastolic pressure) will be measured in patients treated with standard treatment compared to patients treated with ESATRAL with an Omron Digital Automatic Blood Pressure Monitor Hem Arm 7114 with pediatric cuff (mmHg). | Base line, week 12, week 24, week 36 | |
Secondary | Changes in Bone Mineral Density | Difference in bone mineral density (BMD) measured by Dual-energy X-ray Absorptiometry (DXA) (total bone mineral content, BMD lumbar spine and femur neck) in patients treated with standard treatment compared to patients treated with ESATRAL. It will be measured in g/m2]. | Base line, week 24, week 36 | |
Secondary | Changes in Heart Rate | Difference in heart rate measured with Polar RS800CX heart rate monitor in patients treated with standard treatment compared to patients treated with ESATRAL (beats per minute). | Base line, week 12, week 24, week 36 | |
Secondary | Restoration of ovarian function | Changes in ovarian function from interviews conducted by the endocrine physician in patients treated with standard treatment compared to patients treated with ESATRAL (answer: yes, no). | Base line, week 12, week 24, week 36 | |
Secondary | Changes in Height | It will be measured by attaching a Seca scale to the Seca 714 scale (Seca Vogel & Halke GmbH & Co. KG, Hamburg, Germany), with an accuracy of 0.1 cm. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in bodyweight | Difference in bodyweight (kg) with Tanita MC-780MA in patients treated with standard treatment compared to patients treated with ESATRAL. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in corporal composition | Difference in fat mass (kg), and fat free mass (kg) measured with DXA and Tanita MC-780MA in patients treated with standard treatment compared to patients treated with ESATRAL. | Base line, week 12, week 24, week 36 | |
Secondary | Demographic variables | The following demographic variables will be taken to characterize the sample:
Age, type of anorexia (diagnosed in the Hospital), time of evolution of the disease and BMI (BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared). |
Base line, week 12, week 24, week 36 | |
Secondary | Changes in perceived quality of life | Difference in quality of life measured with SF-12v2 (Ware et al., 2009) in patients treated with standard treatment compared to patients treated with ESATRAL. Scoring is on a scale from 0 to 100 where higher score means a better perceived state of health. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in eating attitudes | Difference in attitudes towards food measured with EAT-26 (Garner et al., 1982) in patients treated with standard treatment compared to patients treated with ESATRAL.
Scoring is on a scale from 0 to 78. Higher scores indicate greater risk of an eating disorder and total scores 20 or above are considered to be in the clinical range. |
Base line, week 12, week 24, week 36 | |
Secondary | Changes in compulsive exercise | Difference in compulsive exercise measured with Compulsive Exercise test (CET) in patients treated with standard treatment compared to patients treated with ESATRAL. Scoring is measured on a scale from 0 to 5 where higher score means a worse outcome except for two questions where higher score means better outcome. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in body image | Difference in body image measured through the Multidimensional Body Self Relations Questionnaire (MBSRQ) (Cash, 2000) in patients treated with standard treatment compared to patients treated with ESATRAL. Scoring is measured on a scale from 0 to 5 where the higher the score, the greater the satisfaction with one's own body image. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in agility | Difference in agility measured with the 3 and 10 m Time Up and Go (TUG) test (San Juan et al. 2008) and the Timed Up and Down Stairs (TUDS) test (Gocha et al. 2001) in patients treated with standard treatment compared to patients treated with ESATRAL. In both tests the time necessary to perform the test is taken and the longer the time the worse the agility. | Base line, week 12, week 24, week 36 | |
Secondary | Structured physical activity | Daily time spent in structured ligth, moderate or vigorous intensity (percentage) physical activity will be measured using the ActiGraph GT9X Link to compare patients treated with standard treatment with patients treated with ESATRAL. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in physical performance of the lower extremities | Difference in the physical performance of the lower extremities measured with the Short Physical Performance Battery in patients treated with standard treatment compared to patients treated with ESATRAL. | Base line, week 12, week 24, week 36 | |
Secondary | Changes in functionality | Difference in the function of the participants with respect to day-to-day activities measured with the Barthel Index (Mahoney and Barthel, 1965) in patients treated with standard treatment compared to patients treated with ESATRAL. The range of scores obtained goes from 0 to100 points. A total score of 100 indicates complete self-sufficiency in performance, while a score of zero would indicate absolute dependence. A score obtained between 21 and 60 is indicative of a severe dependency, while scores higher than this limit of 60 points would describe almost all the people who are independent for the execution of these activities. | Base line, week 12, week 24, week 36 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01501396 -
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
|
Phase 2 | |
Withdrawn |
NCT02793102 -
Sensory Workshops and Anorexia Nervosa
|
N/A | |
Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
Completed |
NCT02524301 -
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
|
N/A | |
Active, not recruiting |
NCT00488072 -
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
|
Phase 2 | |
Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
Completed |
NCT00040885 -
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
|
Phase 3 | |
Completed |
NCT00006799 -
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT04007900 -
Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
|
N/A | |
Completed |
NCT00735540 -
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
|
N/A | |
Completed |
NCT00046904 -
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
|
Phase 3 | |
Completed |
NCT04803305 -
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
|
Phase 1 | |
Completed |
NCT05708404 -
Outpatient Treatment of Severe and Enduring Anorexia Nervosa
|
||
Completed |
NCT03283488 -
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
|
Phase 2 | |
Recruiting |
NCT05503147 -
Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
|
Phase 1 | |
Terminated |
NCT01200602 -
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
|
Phase 2 |